[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperuricemia-gout\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperuricemia-gout":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100639576","probiotic-uricase-complex-preparation-for-improving-uric-acid-metabolism-in-patients-with-hyperuricemia-100639576",false,"NCT07613164","Probiotic-Uricase Complex Preparation for Improving Uric Acid Metabolism in Patients With Hyperuricemia","An Exploratory Clinical Study to Evaluate the Effect of a Probiotic-Uricase Complex Preparation on Serum Uric Acid Reduction and Its Regulation of Gut Microbiota Composition and Uric Acid-Related Metabolic Profiles in Patients With Hyperuricemia","Inclusion Criteria:\n\n* Age 18-60 years.\n* Men with serum uric acid levels \\> 420 μmol\u002FL on 2 separate occasions (not on the same day), women with serum uric acid levels \\> 360 μmol\u002FL on 2 separate occasions (not on the same day).\n* Participants must sign an informed consent form and be able to cooperate with sample collection.\n\nExclusion Criteria:\n\n* A history of or current presence of a clearly defined organic intestinal disease, such as intestinal malignant tumor, inflammatory bowel disease, intestinal obstruction, or intestinal polyp.\n* Concurrent severe systemic diseases, including severe cardiovascular or cerebrovascular disease (eg., myocardial infarction within the past 6 months, NYHA Class III-IV heart failure, or uncontrolled hypertension), significant liver function abnormalities (ALT or AST \\> 2 times the upper limit of normal), moderate-to-severe renal insufficiency (eGFR \\\u003C 45 mL\u002Fmin\u002F1.73 m²) or uncontrolled diabetes (HbA1c ≥ 9%).\n* Use of antibiotic, probiotic preparation, or other drugs that may significantly alter the gut microbiota within 4 weeks prior to enrollment, or those requiring continued use of such drugs during the study.\n* Women who are pregnant or lactating, or who plan to become pregnant during the study.\n* Participants with severe tophus or gouty nephropathy.\n* Participants who have participated in another clinical trial within 3 months prior to enrollment.\n* Participants with other health problems that render them unsuitable for enrollment.","ALL","18 Years","60 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"NA","This single-center, open-label, two-arm interventional study aims to evaluate the efficacy and safety of a probiotic-uricase complex preparation in patients with hyperuricemia. Participants aged 18 to 60 years with hyperuricemia will be assigned to either the intervention group or the control group. Participants in the intervention group will receive the probiotic-uricase complex preparation during a 2-week treatment period according to the study protocol in addition to conventional management, while participants in the control group will receive conventional management alone. Blood, urine, and fecal samples will be collected at baseline and during follow-up. The primary goal is to assess the change in serum uric acid from baseline after treatment. Secondary assessments include changes in uric acid-related metabolites in blood, urine, and feces, alterations in gut microbiota composition based on metagenomic analysis, and safety outcomes including laboratory parameters and adverse events. This study will explore whether the probiotic-uricase complex may serve as a safe and effective oral intervention for improving uric acid metabolism in patients with hyperuricemia.",[27],"Hyperuricemia, Gout",[29,30,31,32],"Probiotic Intervention","Hyperuricemia","Gout","Urease","NOT_YET_RECRUITING","2026-05-23",{"date":36,"type":37},"2026-05-29","ACTUAL",{"date":39,"type":21},"2026-05",{"date":41,"type":21},"2029-05",{"name":43,"class":44},"Maanshan Shiqiye Hospital","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100621140","acute-effects-of-a-urate-lowering-bacterial-therapeutic-on-small-intestinal-transcriptomics-and-glycomics-in-healthy-subjects-100621140","NCT07366749","Acute Effects of a Urate-lowering Bacterial Therapeutic on Small Intestinal Transcriptomics and Glycomics in Healthy Subjects","The Acute Effects of a Urate-lowering Probiotic Food Supplement\u002FBacterial Therapeutic on Small Intestinal Transcriptomics and Glycomics in Healthy Subjects","Bugs4U-MoA","Inclusion Criteria:\n\n* Signed informed consent.\n* Age 18-60 years.\n* BMI 18.5 - 29.9 kg\u002Fm².\n* Willing to avoid probiotics, fermented foods, and maintain stable diet\u002Flifestyle for the study duration.\n\nExclusion Criteria:\n\n* Chronic GI, inflammatory, metabolic (including renal), or significant psychiatric disease.\n* Acute infection\u002Fallergy within 2 weeks.\n* Regular use of NSAIDs, antibiotics, steroids, immunomodulators.\n* Alcohol \\>9 units\u002Fweek.\n* Use of recreational drugs, tobacco, or nicotine.\n* Known allergy to local anesthetics or sedatives for gastroscopy.\n* Bleeding disorder or use of anticoagulants.\n* Use of probiotics or antibiotics within 4 weeks prior.\n* Pregnancy, breastfeeding, or planning pregnancy.\n* Any condition deemed by investigator to compromise safety or data integrity",true,{"count":55,"type":21},8,[24],"This is a pilot study investigating how a novel probiotic supplement (BEO001), with and without a dietary fiber (beta-glucan), affects the lining of the small intestine in healthy people. The main goal is to see if a single dose of the probiotic changes gene activity (transcriptomics) and sugar molecule patterns (glycomics) in the gut. Eight participants will take three different treatments (placebo, probiotic alone, probiotic with fiber) in a random order, with at least 10 days between each. A gastroscopy to collect small intestinal tissue samples (biopsies) is performed the morning after each treatment. Blood and breath samples are also collected at these visits to explore effects on metabolism and inflammation. To understand how different sampling methods compare, participants collect stool samples and simple rectal swabs at home before any treatment. Researchers analyze the sugar molecules and bacteria in these samples, then compare them to each other and to the gut tissue samples collected after treatment. This helps determine if easier-to-collect samples can provide similar information to gut biopsies. The study also aims to combine all data (including genetics and diet) to identify key targets for future research and to attempt to grow 'mini-gut' organoids from the biopsies. The results will help design larger future studies in people with high uric acid levels.",[59,27],"Healthy",[61,62,63,64,65,66],"probiotics","gut microbiome","small intestine","transcriptomics","glycomics","urate metabolism","2026-01-16",{"date":69,"type":37},"2026-01-26",{"date":71,"type":21},"2026-02",{"date":73,"type":21},"2026-07",{"name":75,"class":44},"Örebro University, Sweden",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":108,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":76},"100569420","osaka-cardiometabolic-epidemiological-study-ohtori-study-part-2-100569420","NCT06694012","Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2","OCES-2","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* Women who may be pregnant","20 Years",{"count":86,"type":21},2000,"OBSERVATIONAL","The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of Japanese men and women. The investigators will also investigate novel risk factors for metabolic and cardiovascular disease using molecular weight-based metallomics analysis.",[90,91,92,93,94,95,96,97,27,98,99,100,101,102,103,104,105,106,107],"Type 2 Diabetes Mellitus (T2DM)","Type 2 Diabetes","Diabetes Mellitus","Hypertension","Hyperglycemia","Hyperlipidemia","Dyslipidemia","Hyperuricemia or Gout","Obesity","Obesity\u002FEpidemiology","Obesity, Abdominal","Central Obesity","Visceral Fat","Chronic Kidney Disease(CKD)","Atherosclerosis","Metabolic Syndrome","Hepatic Steatosis","Insulin Sensitivity\u002FResistance",[109,93,95,96,30,110,111,112,113,114,115,105,116,117],"Type 2 Diabetes Mellitus","obesity","Abdominal obesity","Visceral fat","Visceral adiposity","Chronic Kidney Disease","Japanese","Insulin Sensitivity","Insulin Resistance","RECRUITING","2024-11-29",{"date":121,"type":37},"2024-12-04",{"date":123,"type":37},"2024-11-01",{"date":125,"type":21},"2050-03-31",{"name":127,"class":44},"Osaka Metropolitan University"]